Skip to main content
SpringerLink
Log in

Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment

  • Published:
Annals of Clinical Psychiatry

Abstract

This study compared the sexual functioning effects as well as the safety and efficacy of bupropion sustained release (bupropion SR) and sertraline. Three hundred sixty-four patients with normal sexual functioning and recurrent major depression were treated with bupropion SR (150–400 mg/day), sertraline (50–200 mg/day), or placebo for 8 weeks in this randomized, double-blind, multicenter study. Patients' depression, sexual functioning, and overall safety were assessed at regular clinic visits. Significantly (P < 0.05) more patients treated with sertraline experienced orgasm dysfunction compared with patients treated with bupropion SR or placebo. Bupropion SR, but not sertraline, was statistically significantly superior to placebo in improving scores on all depression scales by the end of the study. Headache occurred with similar frequency in all groups. Gastrointestinal disturbances occurred more frequently with sertraline; insomnia and agitation occurred more frequently with bupropion SR. Small decreases in mean weight were seen with both active treatments; the placebo group experienced a minor increase in mean weight. Both bupropion SR and sertraline were generally well tolerated, although sertraline was more often associated with sexual dysfunction. Bupropion SR, but not sertraline, was statistically superior to placebo in relieving depression by the end of the study. Bupropion SR may offer advantages over sertraline in treating depressed patients concerned with sexual functioning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Settle EC: Managing antidepressant side effects. Drug Ther 1993; 23(7):17–30

    Google Scholar 

  2. Pollack MH, Rosenbaum JF: Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry 1987; 48:3–8

    Google Scholar 

  3. Mitchell JE, Popkin MK: Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983; 3:76–79

    Google Scholar 

  4. DeLeo D, Magni G: Sexual side effects of antidepressant drugs. Psychosomatics 1983; 24:1076–1082

    Google Scholar 

  5. Herman, JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF: Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51:25–27

    Google Scholar 

  6. Segraves RT: Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monogr 1992; 10:4–10

    Google Scholar 

  7. Hopkins HS: Antidotes for depression-induced sexual dysfunction. Biol Ther Psychiatry 1992; 15:33–36

    Google Scholar 

  8. Jacobsen FM: Fluoxetine-induced sexual dysfunction in an open trial of yohimbine. J Clin Psychiatry 1992; 53:119–122

    Google Scholar 

  9. Nitenson NC, Cole JO: Psychotropic-induced sexual dysfunction. In: Dunner DL, ed. Current Psychiatric Therapy. Philadelphia: Saunders; 1993:353–359

    Google Scholar 

  10. Aizenberg D, Gur S, Zemishlany Z, Granek M, Jeczmien P, Weizman A: Mianserin, a 5-HT2a/2c and α2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1997; 20(3):210–214

    Google Scholar 

  11. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C: The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991; 52:66–68

    Google Scholar 

  12. Sovner R: Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine. J Clin Psychopharmacol 1984; 4:169

    Google Scholar 

  13. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J: Antidepressant efficacy of sertraline: a double-blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51:18–27

    Google Scholar 

  14. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LR, Claghorn JL, Dessain EC, Itil TM, Lautin A: Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51:28–33

    Google Scholar 

  15. Doogan DP, Caillard V: Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49(suppl 8):46–51

    Google Scholar 

  16. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS: Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57(suppl 2):53–62

    Google Scholar 

  17. Segraves RT, Kavoussi R, Hughes AR, Batey SR, Johnston JA, Donahue R, Ascher JA: Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of bupropion sustained release and sertraline treatment. J Clin Psychopharmacol 1999 (in press)

  18. Gitlin MJ: Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55:406–413

    Google Scholar 

  19. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58:532–537

    Google Scholar 

  20. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA: A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther 1998; 20:505–516

    Google Scholar 

  21. Ascher JA, Cole JO, Colin J, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395–401

    Google Scholar 

  22. Ferris RM, Cooper BR: Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 1993; 11(1):2–14

    Google Scholar 

  23. Gardner EA, Johnston JA: Bupropion: an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985; 5:24–29

    Google Scholar 

  24. Modell JG, Katholi CR, Modell JD, DePalma RL: Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997; 61:476–487

    Google Scholar 

  25. Croft H, Settle E, Houser T, Batey SR, Donahue RMJ, Ascher JA: A placebo-controlled comparison of the antidepressant and sexual functioning effects of bupropion sustained release and sertraline. Clin Ther 1999; 21(4):643–658.

    Google Scholar 

  26. American Psychiatric Association: Mood Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Revised. Washington, DC: American Psychiatric Association, 1994:317–345

    Google Scholar 

  27. Hamilton M: A rating scale for depression. J Neurol Neurologic Psychiatry 1960; 23:56–62

    Google Scholar 

  28. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychiatry 1967; 6:278–296

    Google Scholar 

  29. Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TMM: The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995; 52:363–369

    Google Scholar 

  30. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 50–55

  31. Guy W: ECDEU Assessment Manual for Psychopharmacology. US Dept. of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976; 218–222

    Google Scholar 

  32. Salazar WH: Management of depression in the outpatient office. Med Clin North Am 1996; 80(2):431–455

    Google Scholar 

  33. McElroy SL, Keck PE, Friedman LM: Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995; 56(suppl 2):49–55

    Google Scholar 

  34. Wise TN: A model for the assessment of sexual dysfunction etiology. J Clin Psychiatry Monograph 1992; 10(2):5–18

    Google Scholar 

  35. Sertraline (ZOLOFT®) Product Information. Pfizer Inc., 1997

  36. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed dose comparison with placebo. Biol Psychiatry 1995; 38:592–602

    Google Scholar 

  37. Hsu JH, Shen WW: Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25(2):191–201

    Google Scholar 

  38. Harvey KV, Balon R: Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psych 1995; 7(4):189–201

    Google Scholar 

  39. Murdoch D, McTavish D: Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992; 44:604–624

    Google Scholar 

  40. Balon R: Drug holidays to counter sexual dysfunction. Am J Psychiatry 1996; 153(10):1370–1371

    Google Scholar 

  41. Rothschild AJ: Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152:1514–1516

    Google Scholar 

  42. Zajecka J, Tracy K, Mitchell S: Discontinuation symptoms following treatment with serotonin reuptake inhibitors; a literature review. J Clin Psychiatry 1997; 58(7):291–297

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mississippi Neuropsychiatric Clinic, Ridgeland, Mississippi

    Charles C. Coleman MD

  2. Vine Street Clinic, Springfield, Illinois

    Lynn A. Cunningham MD

  3. Glaxo Wellcome Inc., Research Triangle Park, North Carolina

    Vicki J. Foster MSPH (Senior Clinical Research Scientist), Sharyn R. Batey PharmD (Senior Clinical Research Program Head), Rafe M. J. Donahue PhD (Senior Statistician), Trisha L. Houser BA (Senior Clinical Research Scientist) & John A. Ascher MD (Principal Clinical Research Physician)

Authors
  1. Charles C. Coleman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn A. Cunningham MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vicki J. Foster MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sharyn R. Batey PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafe M. J. Donahue PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Trisha L. Houser BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John A. Ascher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coleman, C.C., Cunningham, L.A., Foster, V.J. et al. Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment. Ann Clin Psychiatry 11, 205–215 (1999). https://doi.org/10.1023/A:1022309428886

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022309428886

Search

Navigation